Drug-Resistant Epilepsy Management and Prognosis

Drug-resistant epilepsy (DRE) affects approximately one third of people with epilepsy and is defined by the failure to achieve sustained seizure freedom despite trials of two or more well-chosen antiseizure medications. Patients with DRE face higher risks of injury, comorbidity and premature mortality, underlining the need for prompt recognition and tailored interventions. Management strategies combine optimised pharmacotherapy, neurosurgical evaluation and emerging neuromodulation or dietary therapies. Prognosis hinges on identifying clinical and radiological predictors of treatment response, such as age at onset, seizure type, imaging abnormalities and early treatment failure. Robust prognostic models now integrate longitudinal data—seizure frequency trends and treatment history—to refine individualised risk stratification. Early referral for epilepsy surgery, when a focal structural lesion or clear epileptogenic zone is present, can offer seizure remission rates exceeding 60 %, whereas neuromodulation may benefit those unsuitable for resection. Across low-resource and high-income settings, standardised definitions and treatment algorithms are essential to reduce disparities in care and improve long-term outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Drug-Resistant Epilepsy Management and Prognosis publication trend

The graph below shows the total number of articles in drug-resistant epilepsy management and prognosis across all publications each year (not limited to Nature Index journals).

Technical terms

Drug-resistant epilepsy: Inability to achieve sustained seizure control despite adequate trials of two or more antiepileptic medications.

Antiseizure medication (ASM): Pharmacological agents used to prevent or reduce the frequency of epileptic seizures.

Seizure remission: A sustained period, typically 12 months or more, without epileptic seizures under treatment.

Prognostic factor: A clinical or demographic variable that influences the likelihood of a particular health outcome.

References

1. Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021. Journal of Neurology (2024).
2. Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy. Frontiers in Neurology (2022).
3. Definitions and Risk Factors for Drug-Resistant Epilepsy in an Adult Cohort. Frontiers in Neurology (2021).
4. Clinical, radiological and electrophysiological predictors for drug-resistant epilepsy. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2023).